News und Analysen

Regulatory News:

Lysogene (FR0013233475 – LYS) (Paris:LYS) today announced the amendment of its corporate agenda* for 2020. The annual results for 2019 will be issued on 22 April 2020 instead of

Pfizer today issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.

Dr. Albert Bourla, Chairman

Pfizer today issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.

Dr. Albert Bourla, Chairman

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the fourth quarter and full year ending December 31, 2019 and provided a business update.

This

Agilent Technologies Inc. (NYSE: A) today announced that two of the company’s instruments have received Scientists’ Choice awards. The Agilent 8890 GC system won for Best New Separations Product

Novocure (NASDAQ: NVCR) announced today that preclinical data on Tumor Treating Fields in combination with anti-PD-1 therapy were published in the peer-reviewed journal, Cancer Immunology,

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) , a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and

Regulatory News:

Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, publishes its financial results

LivaNova PLC (NASDAQ:LIVN), ein marktführendes medizintechnisches Innovationsunternehmen, gab heute bekannt, dass sein System Vagus Nerve Stimulation Therapy^® (VNS Therapy) Symmetry™ die

Humana Inc. (NYSE: HUM) announced today several actions in response to the increased spread of the coronavirus (COVID-19).

“As we navigate the spread of the coronavirus, our top priority is the

Regulatory News:

Curadigm, an early-stage nanotechnology company committed to improving treatment outcomes by redefining the therapeutic balance between bioavailability, toxicity, and efficacy

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Vagus Nerve Stimulation Therapy^® (VNS Therapy) System, Symmetry™, earned CE Mark approval

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the fourth quarter and year ended December 31, 2019. Amounts, unless

Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report fourth quarter/year-end 2019 financial results and provide a business update on Thursday

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced the pricing of $200 million aggregate principal amount of 2.625%

Pfizer Inc. (NYSE: PFE) today announced the election of Dr. Susan Hockfield to its Board of Directors, effective immediately. Dr. Hockfield, age 68, was also appointed to the Regulatory and

Pfizer Inc. (NYSE: PFE) today announced the election of Dr. Susan Hockfield to its Board of Directors, effective immediately. Dr. Hockfield, age 68, was also appointed to the Regulatory and

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced that it intends to offer, subject to market conditions and other

Regulatory News:

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE)